Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Slides:



Advertisements
Similar presentations
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Advertisements

Ectopic pregnancy rate increases with the number of retrieved oocytes in autologous in vitro fertilization with non-tubal infertility but not donor/recipient.
Demián Glujovsky, M.D., M.Sc., Cynthia Farquhar, M.D., M.P.H. 
Wendy S. Vitek, M. D. , Jeannine Witmyer, Ph. D. , Sandra A. Carson, M
Laura Londra, M. D. , Caroline Moreau, M. D. , M. P. H. , Ph. D
A giant oocyte in a cohort of retrieved oocytes: does it have any effect on the in vitro fertilization cycle outcome?  Ronit Machtinger, M.D., Joseph.
Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates  Liang Zhou, M.D., Rong Li, M.D., Ph.D., Rong.
Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women.
Extremities of body mass index and their association with pregnancy outcomes in women undergoing in vitro fertilization in the United States  Jennifer.
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
Michael M. Alper, M.D.  Fertility and Sterility 
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Contrasting patterns in in vitro fertilization pregnancy rates among fresh autologous, fresh oocyte donor, and cryopreserved cycles with the use of day.
Ovarian pregnancy after in vitro fertilization
Comparison of fallopian tube sperm perfusion and intrauterine tuboperitoneal insemination: a prospective randomized study  Leonidas Mamas, M.D., Ph.D. 
Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy  Ewa Nowak-Markwitz,
Medical treatment of ectopic pregnancy: a committee opinion
The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society.
Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D. 
How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization  Robert L. Klitzman, M.D.  Fertility.
The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility  Alexander M. Quaas, M.D.,
Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization  Ginny Mounce,
Ectopic pregnancy rate increases with the number of retrieved oocytes in autologous in vitro fertilization with non-tubal infertility but not donor/recipient.
Pregnancy-related fibroid reduction
A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data 
Two interesting cases of ovarian pregnancy after in vitro fertilization–embryo transfer and its successful laparoscopic management  Selvaraj Priya, M.D.,
Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review  Seema Menon, M.D., John.
Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis  Cui Hong Zheng, M.D., Ph.D.,
Marcus W. Jurema, M. D. , Andrea D. Vieira, M. D
Influence of acupuncture stimulation on pregnancy rates for women undergoing embryo transfer  Caroline Smith, Ph.D., Meaghan Coyle, B.Hlth.Sc. (Acup.),
A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization  Laura Detti, M.D., Daniel B. Williams, M.D., Jared.
Association between prior appendectomy and/or tonsillectomy in women and subsequent pregnancy rate: a cohort study  Li Wei, Ph.D., Thomas MacDonald, M.D.,
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
Variations in l-selectin ligand expression in the luteal-phase endometrium after final oocyte maturation with human chorionic gonadotropin compared with.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis  Laura P. Smith, M.D.,
Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.
Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility  Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,
Ovarian hyperstimulation secondary to ectopic secretion of follicle-stimulating hormone. Literature review prompted by a case  Jorge Burgos, M.D., Patricia.
Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles  Karin.
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,
Jennifer F. Kawwass, M. D. , Sara Crawford, Ph. D. , Donna R
Aaron K. Styer, M. D. , Diane L. Wright, Ph. D. , H. C. L. D. , Anne M
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
Effectiveness of highly purified human menopausal gonadotropin vs
Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Fertility and Sterility: an evaluation
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Sedigheh Borna, M.D., Azita Nasery, M.D.  Fertility and Sterility 
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis  Ernesto Bosch, M.D., Elena.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr  Murat Arslan, M.D.,
Fertility and Sterility
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study  Ahmed Badawy, M.D., Aboubakr.
Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories  Melissa C. Yih, M.D.,
In vitro sildenafil citrate use as a sperm motility stimulant
Society for Assisted Reproductive Technology and assisted reproductive technology in the United States: a 2016 update  James P. Toner, M.D., Ph.D., Charles.
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization  Ginny Mounce,
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
The cumulative probability of liveborn multiples after in vitro fertilization: a cohort study of more than 10,000 women  Beth A. Malizia, M.D., Laura.
Not all twins are monozygotic after elective single embryo transfer: analysis of 32,600 elective single embryo transfer cycles as reported to the Society.
Presentation transcript:

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization?  Laura Londra, M.D., Caroline Moreau, M.D., M.P.H., Ph.D., Donna Strobino, Ph.D., Aarti Bhasin, M.D., M.P.H., Yulian Zhao, M.D., Ph.D., H.C.L.D.  Fertility and Sterility  Volume 106, Issue 3, Pages 666-672 (September 2016) DOI: 10.1016/j.fertnstert.2016.05.019 Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Description of the process for the selection of the cohort of cycles. Fertility and Sterility 2016 106, 666-672DOI: (10.1016/j.fertnstert.2016.05.019) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.